Scholarlink

Purpose of the Review <p>Glucocorticoid (GC) toxicity is a major concern in the management of giant cell arteritis (GCA). Tocilizumab (TCZ) has been introduced as a GC-sparing agent in GCA. This review critically analyses the extent of the GC-sparing capacity of TCZ and explores its impact on molecular and imaging findings.</p> Recent Findings <p>Two randomized controlled trials investigated the GC-sparing potential of TCZ in the treatment of GCA. Four Proof-of-concept studies have investigated the extent to which GC exposure can be further minimized. Recent evidence highlights the chronicity of GCA, emphasizing the need for low-toxicity treatment strategies and advocating for long-term follow-up.</p> Summary <p>Reducing GC toxicity is one of the most important trends in the management of GCA. New treatment strategies include TCZ and reducing GC exposure and toxicity in patients diagnosed with GCA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Precision Over Prednisone: Innovative Treatment Strategies for Giant Cell Arteritis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月22日

查看全文
  • Andrea D. Gloor,
  • Mads Engell Refstrup Sørensen,
  • Francesco Muratore,
  • Peter M. Villiger,
  • Lisa Christ

摘要

Purpose of the Review

Glucocorticoid (GC) toxicity is a major concern in the management of giant cell arteritis (GCA). Tocilizumab (TCZ) has been introduced as a GC-sparing agent in GCA. This review critically analyses the extent of the GC-sparing capacity of TCZ and explores its impact on molecular and imaging findings.

Recent Findings

Two randomized controlled trials investigated the GC-sparing potential of TCZ in the treatment of GCA. Four Proof-of-concept studies have investigated the extent to which GC exposure can be further minimized. Recent evidence highlights the chronicity of GCA, emphasizing the need for low-toxicity treatment strategies and advocating for long-term follow-up.

Summary

Reducing GC toxicity is one of the most important trends in the management of GCA. New treatment strategies include TCZ and reducing GC exposure and toxicity in patients diagnosed with GCA.